Table 1 Summary of PO clinical trials tested in the PFSratio-based analysis
Study | year(s) | Site | Tumor types treated | Type of molecular screening | Primary endpoint | PFSratio analysis | n° of patients evaluable for PFSratio |
|---|---|---|---|---|---|---|---|
WINTHER (NCT01856296) | 2013–2015 | Multicentric, international | Advanced cancers that progressed on standard Tx | Targeted genomic (236 cancer-related genes panel) + transcriptomic (microarrays) | PFSratio | Proportion of patients with PFSratio >1.5 | 107 |
MASTER (NCT03127215) | 2012–ongoing | Multicentric, national | Advanced rare cancers or cancers in young patients ( < 51 years) that progressed on standard Tx | WGS/WES + transcriptomic (RNAseq) | Feasibility and clinical relevance of comprehensive molecular analysis in rare cancers | Proportion of patients with PFSratio >1.3 | 255 |
MOSCATO 01 (NCT01566019) | 2011–2016 | Monocentric | Advanced cancers that progressed on standard Tx | Targeted genomic (40-75 cancer-related genes panel) or WES + transcriptomic (RNAseq) | PFSratio | Proportion of patients with PFSratio >1.3 | 194 |
POG570 (NCT02155621) | 2012– ongoing | Monocentric | Advanced cancers that progressed on standard Tx | WGS + transcriptomic (RNAseq) | Feasibility and clinical relevance of comprehensive molecular analysis in advanced cancers | Not done | 190 |
SHIVA (NCT01771458) | 2012–2014 | Multicentric, national | Advanced cancers that progressed on standard Tx | Targeted genomic (45 cancer-related genes panel) + IHC for ER, PR and AR | PFS | Proportion of patients with PFSratio >1.3 | 95 |
